Moreover, the use of bispecific CAR-T cells (e.g., anti-BCMA/CS1) could overcome monospecific CAR-T cell therapy resistance by greatly increasing tumor cell recognition and killing and by reducing the risk of antigen escape [161]. This evidence concerns the gene TNFRSF17 and neoplasm.